ELVN Relative Valuation
ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ELVN is overvalued; if below, it's undervalued.
Historical Valuation
Enliven Therapeutics Inc (ELVN) is now in the Fair zone, suggesting that its current forward PS ratio of 111115.34 is considered Fairly compared with the five-year average of -9.29. The fair price of Enliven Therapeutics Inc (ELVN) is between 7.88 to 20.49 according to relative valuation methord.
Relative Value
Fair Zone
7.88-20.49
Current Price：15.00
Fair
-8.87
PE
1Y
3Y
5Y
-3.19
EV/EBITDA
Enliven Therapeutics Inc. (ELVN) has a current EV/EBITDA of -3.19. The 5-year average EV/EBITDA is -4.66. The thresholds are as follows: Strongly Undervalued below -9.43, Undervalued between -9.43 and -7.04, Fairly Valued between -2.27 and -7.04, Overvalued between -2.27 and 0.12, and Strongly Overvalued above 0.12. The current Forward EV/EBITDA of -3.19 falls within the Historic Trend Line -Fairly Valued range.
-3.59
EV/EBIT
Enliven Therapeutics Inc. (ELVN) has a current EV/EBIT of -3.59. The 5-year average EV/EBIT is -5.78. The thresholds are as follows: Strongly Undervalued below -10.50, Undervalued between -10.50 and -8.14, Fairly Valued between -3.42 and -8.14, Overvalued between -3.42 and -1.06, and Strongly Overvalued above -1.06. The current Forward EV/EBIT of -3.59 falls within the Historic Trend Line -Fairly Valued range.
111115.34
PS
Enliven Therapeutics Inc. (ELVN) has a current PS of 111115.34. The 5-year average PS is 92648.40. The thresholds are as follows: Strongly Undervalued below -106195.18, Undervalued between -106195.18 and -6773.39, Fairly Valued between 192070.18 and -6773.39, Overvalued between 192070.18 and 291491.97, and Strongly Overvalued above 291491.97. The current Forward PS of 111115.34 falls within the Historic Trend Line -Fairly Valued range.
-10.60
P/OCF
Enliven Therapeutics Inc. (ELVN) has a current P/OCF of -10.60. The 5-year average P/OCF is -10.81. The thresholds are as follows: Strongly Undervalued below -18.93, Undervalued between -18.93 and -14.87, Fairly Valued between -6.75 and -14.87, Overvalued between -6.75 and -2.70, and Strongly Overvalued above -2.70. The current Forward P/OCF of -10.60 falls within the Historic Trend Line -Fairly Valued range.
-10.33
P/FCF
Enliven Therapeutics Inc. (ELVN) has a current P/FCF of -10.33. The 5-year average P/FCF is -5.18. The thresholds are as follows: Strongly Undervalued below -17.96, Undervalued between -17.96 and -11.57, Fairly Valued between 1.21 and -11.57, Overvalued between 1.21 and 7.61, and Strongly Overvalued above 7.61. The current Forward P/FCF of -10.33 falls within the Historic Trend Line -Fairly Valued range.
Enliven Therapeutics Inc (ELVN) has a current Price-to-Book (P/B) ratio of 1.93. Compared to its 3-year average P/B ratio of 2.69 , the current P/B ratio is approximately -28.07% higher. Relative to its 5-year average P/B ratio of 2.69, the current P/B ratio is about -28.07% higher. Enliven Therapeutics Inc (ELVN) has a Forward Free Cash Flow (FCF) yield of approximately -7.79%. Compared to its 3-year average FCF yield of -7.04%, the current FCF yield is approximately 10.61% lower. Relative to its 5-year average FCF yield of -7.04% , the current FCF yield is about 10.61% lower.
1.93
P/B
Median3y
2.69
Median5y
2.69
-7.79
FCF Yield
Median3y
-7.04
Median5y
-7.04
Competitors Valuation Multiple
The average P/S ratio for ELVN's competitors is 18520.62, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN) exhibits a P/S ratio of 111115.34, which is 499.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ELVN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ELVN in the past 1 year is driven by Unknown.
People Also Watch
OLPX
Olaplex Holdings Inc
1.65USD
22.22%
CMCO
Columbus McKinnon Corp
18.74USD
-3.35%
TUYA
Tuya Inc
2.28USD
1.33%
ASPN
Aspen Aerogels Inc
3.24USD
-2.70%
REAL
RealReal Inc
16.45USD
0.49%
ICHR
Ichor Holdings Ltd
23.61USD
3.60%
ARR
ARMOUR Residential REIT Inc
18.13USD
-0.49%
VTOL
Bristow Group Inc
38.13USD
-3.15%
NRDS
NerdWallet Inc
13.75USD
2.00%
Frequently Asked Questions
Is Enliven Therapeutics Inc (ELVN) currently overvalued or undervalued?
Enliven Therapeutics Inc (ELVN) is now in the Fair zone, suggesting that its current forward PS ratio of 111115.34 is considered Fairly compared with the five-year average of -9.29. The fair price of Enliven Therapeutics Inc (ELVN) is between 7.88 to 20.49 according to relative valuation methord.
What is Enliven Therapeutics Inc (ELVN) fair value?
ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Enliven Therapeutics Inc (ELVN) is between 7.88 to 20.49 according to relative valuation methord.
How does ELVN's valuation metrics compare to the industry average?
The average P/S ratio for ELVN's competitors is 18520.62, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN) exhibits a P/S ratio of 111115.34, which is 499.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Enliven Therapeutics Inc (ELVN) as of Jan 07 2026?
As of Jan 07 2026, Enliven Therapeutics Inc (ELVN) has a P/B ratio of 1.93. This indicates that the market values ELVN at 1.93 times its book value.
What is the current FCF Yield for Enliven Therapeutics Inc (ELVN) as of Jan 07 2026?
As of Jan 07 2026, Enliven Therapeutics Inc (ELVN) has a FCF Yield of -7.79%. This means that for every dollar of Enliven Therapeutics Inc’s market capitalization, the company generates -7.79 cents in free cash flow.
What is the current Forward P/E ratio for Enliven Therapeutics Inc (ELVN) as of Jan 07 2026?
As of Jan 07 2026, Enliven Therapeutics Inc (ELVN) has a Forward P/E ratio of -8.87. This means the market is willing to pay $-8.87 for every dollar of Enliven Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Enliven Therapeutics Inc (ELVN) as of Jan 07 2026?
As of Jan 07 2026, Enliven Therapeutics Inc (ELVN) has a Forward P/S ratio of 111115.34. This means the market is valuing ELVN at $111115.34 for every dollar of expected revenue over the next 12 months.